Clinical Trial Update: Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating botulinum toxin type A (Dysport) as an adjunct to rehabilitation for primary myofascial pain syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myofascial Pain Syndrome

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Myofascial Pain Syndromes | Phase 2 | Status: COMPLETED